Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor

(Yates Public Relations) Aileron Therapeutics announced today that its collaborators, James E. Bradner, M.D., of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, Ph.D., Professor of Chemistry at Harvard University, published research in Nature entitled, “Direct Inhibition of the Notch Transcription Factor Complex” showing that stapled peptides can potently and directly inhibit the transcription factor Notch1. This validates the potential for Stapled Peptides to modulate previously untargetable intracellular biological targets.

source : www.eurekalert.org

Related News:

• NTU Researchers Complete The World’s First In-depth Study Of The Malaria Parasite Genome
• Study Suggests Slide-On(R) Endosheath(R) System Provides Several Advantages Over Traditional Germicidal Immersion
• World’s first in-depth study of the malaria parasite genome
• York Study Maps The Effects Of Acupuncture On The Brain
• Study Finds Some Vegetative Patients Show Awareness, Raising Ethical Questions
• EMEA Gives Official Scientific Advice On Clinical Phase IIb Efficacy Study Of Inecalcitol In Hormone-refractory Prostate Cancer
• Cancer Study Yields Results
• Fat Behaves Differently In Patients With Polycistic Ovary Syndrome
• PROLOR Biotech Reports Positive Top-Line Results From Phase I Study Of Its Longer-Acting Version Of Human Growth Hormone
• Kaiser Study Compares Two AMD Treatments; "Eye Stroke" Prevalent Worldwide; New Data On Vision And Elders’ Risk Of Falling

Details :
Submited at Wednesday, November 11th, 2009 at 7:00 pm on Cancer and Oncology by robert
Comment RSS 2.0 - leave a comment - trackback